Lung Cancer Considered
Science & Technology News
Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. Lung Cancer considered is funded in part by AstraZeneca, Genentech, Daiichi Sankyo, Inc., and Takeda
Location:
United States
Genres:
Science & Technology News
Description:
Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. Lung Cancer considered is funded in part by AstraZeneca, Genentech, Daiichi Sankyo, Inc., and Takeda
Language:
English
Website:
https://www.iaslc.org/
KRAS in NSCLC: Beyond G12C
Duration:00:46:03
FDA Approval: Adjuvant Alectinib for Resected NSCLC
Duration:00:38:13
IASLC DEI Initiative Global Member Survey
Duration:00:27:08
FDA Approval: FLAURA2, First Line Osimertinib Plus Chemotherapy for EGFR NSCLC
Duration:00:47:19
ELCC 2024 Highlights
Duration:00:58:55
Emerging Agents In Small Cell Lung Cancer
Duration:00:41:23
Radiopharmaceuticals and Lung Cancer
Duration:00:54:35
FDA Approval: 1L Amivantamab plus Chemotherapy for EGFR Exon 20 NSCLC
Duration:00:28:40
Seminal Trials: Nivolumab Phase I Trial & Immunotherapy for NSCLC
Duration:00:32:42
From the Basics to Next Line Therapy: ALK + NSCLC
Duration:00:46:09
Best Practice for RET NSCLC
Duration:00:34:22
Biomarkers in Lung Cancer: Barriers to Implementation
Duration:00:45:27
LCC in Mandarin Chinese: Barriers to Biomarker Testing
Duration:00:28:12
LCC in Cantonese Chinese: Barriers to Biomarker Testing
Duration:00:39:58
LCC in French: Barriers to Biomarker Testing
Duration:00:39:30
LCC in Portuguese: Barriers to Biomarker Testing
Duration:00:36:23
LCC in French Canadian: Barriers to Biomarker Testing
Duration:00:45:45
LCC in Japanese: Barriers to Biomarker Testing
Duration:00:33:50
LCC in Spanish: Barriers to Biomarker Testing
Duration:00:38:31
The IASLC’s 50th Anniversary and New Strategic Plan
Duration:00:37:07